Loading clinical trials...
Loading clinical trials...
This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Leal Therapeutics, Inc
NCT07294144 · ALS (Amyotrophic Lateral Sclerosis)
NCT07233148 · Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), and more
NCT07571174 · Amyotrophic Lateral Sclerosis
NCT07369076 · Amyotrophic Lateral Sclerosis (ALS)
NCT03489278 · Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, and more
University Hospital Schleswig-Holstein, Campus Lübeck
Lübeck
Istituto Neurologico "Carlo Besta"
Milan
AOU Città della Salute e della Scienza di Torino
Torino
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions